Literature DB >> 10950539

Risk in cardiovascular disease. Merit of using risk reduction rather than absolute risk for lipid lowering drugs.

R Neary, S Ramachandran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10950539      PMCID： PMC1118171     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  12 in total

1.  Coronary and cardiovascular risk estimation for primary prevention: validation of a new Sheffield table in the 1995 Scottish health survey population.

Authors:  E J Wallis; L E Ramsay; I Ul Haq; P Ghahramani; P R Jackson; K Rowland-Yeo; W W Yeo
Journal:  BMJ       Date:  2000-03-11

2.  Should treatment recommendations for lipid lowering drugs be based on absolute coronary risk or risk reduction?

Authors:  S Ramachandran; J M French; M P Vanderpump; P Croft; R H Neary
Journal:  BMJ       Date:  2000-03-11

3.  Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods.

Authors:  C G Isles; L D Ritchie; P Murchie; J Norrie
Journal:  BMJ       Date:  2000-03-11

4.  1996 National Heart Foundation clinical guidelines for the assessment and management of dyslipidaemia. Dyslipidaemia Advisory Group on behalf of the scientific committee of the National Heart Foundation of New Zealand.

Authors: 
Journal:  N Z Med J       Date:  1996-06-28

5.  Hypercholesterolaemia in borderline hypothyroidism. Stage of premyxoedema.

Authors:  P B Fowler; J Swale; H Andrews
Journal:  Lancet       Date:  1970-09-05       Impact factor: 79.321

6.  Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated.

Authors:  S Baker; P Priest; R Jackson
Journal:  BMJ       Date:  2000-03-11

7.  West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Authors:  J R Downs; M Clearfield; S Weis; E Whitney; D R Shapiro; P A Beere; A Langendorfer; E A Stein; W Kruyer; A M Gotto
Journal:  JAMA       Date:  1998-05-27       Impact factor: 56.272

9.  By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease?

Authors:  M R Law; N J Wald; S G Thompson
Journal:  BMJ       Date:  1994-02-05

10.  Indications for cholesterol-lowering medication: comparison of risk-assessment methods.

Authors:  P N Durrington; H Prais; D Bhatnagar; M France; V Crowley; J Khan; J Morgan
Journal:  Lancet       Date:  1999-01-23       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.